RT Journal Article
SR Electronic
T1 A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.17.24310517
DO 10.1101/2024.07.17.24310517
A1 Peterson, Ross D.
A1 Guarneiri, Liana L.
A1 Adams, Caryn G.
A1 Wilcox, Meredith L.
A1 Clark, Anthony J.
A1 Rudemiller, Nathan P.
A1 Maki, Kevin C.
A1 Malinczak, Carrie-Anne
YR 2024
UL http://medrxiv.org/content/early/2024/07/17/2024.07.17.24310517.abstract
AB Background Recombinant human lactoferrin (rhLF) is of commercial interest for support of the immune system and iron homeostasis but is not currently available as a food ingredient.Objective The objective was to evaluate the immunogenicity/alloimmunization potential of Helaina rhLF (effera™) from K. phaffii over a 28-day period compared to bovine LF (bLF). It was hypothesized that rhLF would have an equal or lower immunogenic potential compared to bLF, which is permitted for use in conventional foods and infant formula in the EU and US.Methods Study 1 was a randomized, double-blind, parallel arm, controlled trial where 66 healthy adults were randomly allocated to 1 of 3 groups: high-dose rhLF (3.4 g/d), low-dose rhLF (0.34 g/d), or bLF (3.4 g/d) (clinicaltrials.gov: NCT06012669). Participants completed a 28-day (Day 28) supplementation period followed by a 28-day washout period (Day 56) and an additional 28-day follow-up period (Day 84). Study 2 was a 12-week observational study with no intervention that enrolled 24 healthy adults. In both studies, fasting blood was obtained on Days 0, 28, 56, and 84 for analysis of anti-bLF and anti-hLF antibody levels as the primary endpoint as well as other secondary safety endpoints including complete blood count, iron biomarkers, and metabolic panel.Results In Study 1, the change from baseline to Day 56 in serum anti-bLF antibodies in the bLF group (least squares geometric mean and 95% confidence interval for the post/pre ratio: 3.01; 2.08, 4.35) was greater than the changes in serum anti-hLF antibodies in the low-dose rhLF (1.07; 0.77, 1.49; P<0.001) and high-dose rhLF (1.02; 0.62, 1.70; P<0.001) groups. In Study 2, the post/pre ratio at Day 56 in serum anti-hLF and anti-bLF antibodies were 1.00 (0.93, 1.08) and 1.01 (0.94, 1.09), respectively, confirming no change in anti-hLF antibodies in Study 1 or Study 2. Changes in all safety outcomes in Study 1 were similar between groups and within normal ranges.Conclusion These results support the safety and tolerability of efferaTM as a food ingredient at an intake level up to 3.4 g/d in healthy adults.Competing Interest StatementHelaina Inc. funded this research and was involved in the study design, interpretation of data, writing of the report, and the decision to submit the report for publication.Clinical TrialNCT06012669Funding StatementHelaina Inc. funded this research and was involved in the study design, interpretation of data, writing of the report, and the decision to submit the report for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Western-Copernicus Group (WCG) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData described in the manuscript and analytical code will be made available upon reasonable request.